Revenue: The sum of all revenue fields included for a company's operating activities.
Apellis Pharmaceuticals, Inc. (APLS) had Revenue of $166.80M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
|
Revenue |
$166.80M |
$-92.22M |
|
$34.36M |
|
$132.44M |
|
$250.12M |
|
$-83.33M |
|
$-8.56M |
|
$-91.88M |
|
$-91.88M |
|
$-92.22M |
|
$-92.22M |
|
$-92.22M |
|
$-92.22M |
|
$-83.33M |
|
$-82.29M |
|
125.45M |
|
125.45M |
|
$-0.74 |
|
$-0.74 |
|
| Balance Sheet Financials | |
$727.72M |
|
$2.51M |
|
$79.57M |
|
$807.28M |
|
$178.38M |
|
$453.42M |
|
$464.69M |
|
$643.07M |
|
$164.22M |
|
$164.22M |
|
$164.22M |
|
125.66M |
|
| Cash Flow Statement Financials | |
$-53.41M |
|
$-0.01M |
|
$0.27M |
|
$412.61M |
|
$359.83M |
|
$-52.78M |
|
$27.37M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.08 |
|
-- |
|
-- |
|
0.73 |
|
2.76 |
|
79.40% |
|
-49.96% |
|
-49.96% |
|
-- |
|
-55.09% |
|
-55.29% |
|
$-53.42M |
|
-- |
|
-- |
|
-- |
|
0.21 |
|
0.42 |
|
0.71 |
|
126.93 |
|
-56.16% |
|
-56.16% |
|
-11.42% |
|
-14.93% |
|
$1.31 |
|
$-0.43 |
|
$-0.43 |
|